ArticleACS pharmacology & translational science2025

Targeting Metabolic Vulnerabilities Reveals Hexokinase 2 as a Key Mediator of Resistance to Osimertinib in Non-Small Cell Lung Cancer Models.

Yizhen Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.